Literature DB >> 11355302

Molecular genetic alterations in glioblastomas with oligodendroglial component.

J A Kraus1, K Lamszus, N Glesmann, M Beck, M Wolter, M Sabel, D Krex, T Klockgether, G Reifenberger, U Schlegel.   

Abstract

Glioblastoma multiforme is the most malignant astrocytic glioma and usually resistant to chemotherapy. A small fraction of glioblastomas may contain areas with histological features of oligodendroglial differentiation. To determine the molecular genetic alterations in such "glioblastomas with oligodendroglial component", we investigated 13 of these tumors for genetic alterations and/or expression of the TP53, CDKN2A, PTEN, and EGFR genes. In addition, we performed microsatellite analyses for loss of heterozygosity (LOH) on chromosome arms 1p, 19q and 10q. None of tumors showed evidence for LOH on 10q. LOH on 1p was detected in 3 tumors, 1 of which additionally showed LOH on 19q. The 3 tumors with LOH on 1p showed neither TP53 mutations nor nuclear p53 accumulation. In contrast, 9 of 10 tumors without demonstrated losses on 1p showed nuclear p53 accumulation. TP53 mutations were identified in 3 of these cases. Further aberrations detected were epidermal growth factor receptor (EGFR) overexpression (3 of 13 tumors), homozygous CDKN2A deletion (2 of 11 tumors), and PTEN mutation (1 of 13 tumors). Taken together, our results indicate that "glioblastomas with oligodendroglial component" carry heterogeneous genetic alterations. LOH on 10q, PTEN mutation, and homozygous CDKN2A deletion appear to be less common in these tumors as compared to ordinary glioblastomas. Furthermore, a subset of these tumors demonstrates LOH on 1p, i.e., an alteration that has recently been linked to chemosensitivity and good prognosis in anaplastic oligodendrogliomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355302     DOI: 10.1007/s004010000258

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  34 in total

1.  Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma.

Authors:  A Broniscer; R G Tatevossian; N D Sabin; P Klimo; J Dalton; R Lee; A Gajjar; D W Ellison
Journal:  Neuropathol Appl Neurobiol       Date:  2014-04       Impact factor: 8.090

2.  MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1.

Authors:  Zhiguo Liu; Yuguang Liu; Lianling Li; Zhenkuan Xu; Baibin Bi; Yunyan Wang; Jian Yi Li
Journal:  Tumour Biol       Date:  2014-07-16

3.  Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.

Authors:  Sang Yun Ha; So Young Kang; In-Gu Do; Yeon-Lim Suh
Journal:  J Neurooncol       Date:  2013-02-15       Impact factor: 4.130

4.  Success at last: a molecular factor that informs treatment.

Authors:  Andrew B Lassman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 5.  Pathology and molecular genetics of astrocytic gliomas.

Authors:  Guido Reifenberger; Vincent Peter Collins
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

6.  A multi-resolution textural approach to diagnostic neuropathology reporting.

Authors:  Mohammad Faizal Ahmad Fauzi; Hamza Numan Gokozan; Brad Elder; Vinay K Puduvalli; Christopher R Pierson; José Javier Otero; Metin N Gurcan
Journal:  J Neurooncol       Date:  2015-08-09       Impact factor: 4.130

7.  Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.

Authors:  Hideaki Yokoo; Sumihito Nobusawa; Hirohide Takebayashi; Kazuhiro Ikenaka; Koji Isoda; Makoto Kamiya; Atsushi Sasaki; Junko Hirato; Yoichi Nakazato
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis.

Authors:  Luciana Wernersbach Pinto; Maria Betania Mahler Araújo; Andre L Vettore; Liana Wernersbach; André Campana C Leite; Leila Maria C Chimelli; Fernando Augusto Soares
Journal:  Virchows Arch       Date:  2008-05       Impact factor: 4.064

9.  Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.

Authors:  Hiroaki Takeuchi; Toshihiko Kubota; Ryuhei Kitai; Ken Matsuda; Norichika Hashimoto; Kazufumi Sato
Journal:  J Neurooncol       Date:  2008-09-10       Impact factor: 4.130

10.  Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.

Authors:  Christina L Appin; Jingjing Gao; Candace Chisolm; Mike Torian; Dianne Alexis; Cristina Vincentelli; Matthew J Schniederjan; Costas Hadjipanayis; Jeffrey J Olson; Stephen Hunter; Chunhai Hao; Daniel J Brat
Journal:  Brain Pathol       Date:  2013-01-30       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.